Correlation Between Infant Bacterial and Q Linea

Can any of the company-specific risk be diversified away by investing in both Infant Bacterial and Q Linea at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Infant Bacterial and Q Linea into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Infant Bacterial Therapeutics and Q linea AB, you can compare the effects of market volatilities on Infant Bacterial and Q Linea and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Infant Bacterial with a short position of Q Linea. Check out your portfolio center. Please also check ongoing floating volatility patterns of Infant Bacterial and Q Linea.

Diversification Opportunities for Infant Bacterial and Q Linea

-0.66

Correlation Coefficient

Infant Bacterial  Q Linea

Excellent diversification

The 3 months correlation between Infant and QLINEA is -0.66. Overlapping area represents the amount of risk that can be diversified away by holding Infant Bacterial Therapeutics and Q linea AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Q linea AB and Infant Bacterial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Infant Bacterial Therapeutics are associated (or correlated) with Q Linea. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Q linea AB has no effect on the direction of Infant Bacterial i.e., Infant Bacterial and Q Linea go up and down completely randomly.

Pair Corralation between Infant Bacterial and Q Linea

Assuming the 90 days trading horizon Infant Bacterial Therapeutics is expected to generate 1.16 times more return on investment than Q Linea. However, Infant Bacterial is 1.16 times more volatile than Q linea AB. It trades about 0.17 of its potential returns per unit of risk. Q linea AB is currently generating about -0.36 per unit of risk. If you would invest  3,300  in Infant Bacterial Therapeutics on September 23, 2024 and sell it today you would earn a total of  2,600  from holding Infant Bacterial Therapeutics or generate 78.79% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Infant Bacterial Therapeutics  vs.  Q linea AB

Infant Bacterial

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Infant Bacterial Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Infant Bacterial unveiled solid returns over the last few months and may actually be approaching a breakup point.

Q linea AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Q linea AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Infant Bacterial and Q Linea

The main advantage of trading using opposite Infant Bacterial and Q Linea positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Infant Bacterial position performs unexpectedly, Q Linea can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Q Linea will offset losses from the drop in Q Linea's long position.

The idea behind Infant Bacterial Therapeutics and Q linea AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.